A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Status:
Recruiting
Trial end date:
2023-05-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of
JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose
Expansion).